NCT06422533View on ClinicalTrials.gov

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

NARecruitingINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

August 30, 2025

Conditions
Hematologic NeoplasmsNeutropenia
Interventions
DRUG

Ceftolozane/tazobactam

Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days

DRUG

Piperacillin/tazobactam

Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days

Trial Locations (1)

14080

RECRUITING

Instituto Nacional de Cancerologia, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cancerologia de Mexico

OTHER